Scholarlink

<p>Effective management of prostate cancer requires an approach that integrates oncological intent with careful consideration of coexisting comorbidities and functional reserve. This podcast explores how chronic health conditions, frailty and quality-of-life factors influence therapeutic choices across the disease continuum. In localised disease, long-term data demonstrating comparable survival between surgery, radiotherapy and active monitoring have reframed the rationale for radical intervention. Treatment decisions are now increasingly guided by competing health risks, anticipated life expectancy and patient preference. In advanced disease, treatment intensification with systemic combination therapy has extended survival but introduced new complexity. The cardiovascular, metabolic and cognitive toxicities of androgen deprivation therapy (ADT) necessitate individualised consideration of intermittent therapy or de-escalation for patients with substantial comorbidity. With the expanding use of triplet regimens in metastatic hormone-sensitive disease, assessing physiological rather than chronological age has become essential. The discussion further highlights the role of structured oncogeriatric assessment in optimising care. Tools such as the Rockwood Clinical Frailty Scale, G8 screening tool and comprehensive geriatric assessment (CGA) provide a systematic framework for evaluating frailty, polypharmacy, cognition and function, supporting balanced decisions about treatment escalation and supportive interventions. Collectively, the dialogue underscores a shift towards holistic, multidisciplinary decision-making that aligns cancer control with broader health, independence and wellbeing. Embedding frailty-informed assessment into prostate cancer pathways represents a necessary evolution towards truly personalised care.</p><p><MediaObject ID="MOESM1"> <VideoObject FileRef="MediaObjects/40487_2025_407_MOESM1_ESM.mp4" VideoID="4zfj7XC3xU4DzMqkVZ2LpY"> <Caption Language="En" xml:lang="en"> <CaptionContent> <p>Podcast Video (MP4 314221 KB)</p> </CaptionContent> </Caption> </VideoObject> </MediaObject></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A Podcast

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Peter Whelan,
  • Kirsty Balachandran,
  • Kenrick Ng

摘要

Effective management of prostate cancer requires an approach that integrates oncological intent with careful consideration of coexisting comorbidities and functional reserve. This podcast explores how chronic health conditions, frailty and quality-of-life factors influence therapeutic choices across the disease continuum. In localised disease, long-term data demonstrating comparable survival between surgery, radiotherapy and active monitoring have reframed the rationale for radical intervention. Treatment decisions are now increasingly guided by competing health risks, anticipated life expectancy and patient preference. In advanced disease, treatment intensification with systemic combination therapy has extended survival but introduced new complexity. The cardiovascular, metabolic and cognitive toxicities of androgen deprivation therapy (ADT) necessitate individualised consideration of intermittent therapy or de-escalation for patients with substantial comorbidity. With the expanding use of triplet regimens in metastatic hormone-sensitive disease, assessing physiological rather than chronological age has become essential. The discussion further highlights the role of structured oncogeriatric assessment in optimising care. Tools such as the Rockwood Clinical Frailty Scale, G8 screening tool and comprehensive geriatric assessment (CGA) provide a systematic framework for evaluating frailty, polypharmacy, cognition and function, supporting balanced decisions about treatment escalation and supportive interventions. Collectively, the dialogue underscores a shift towards holistic, multidisciplinary decision-making that aligns cancer control with broader health, independence and wellbeing. Embedding frailty-informed assessment into prostate cancer pathways represents a necessary evolution towards truly personalised care.

Podcast Video (MP4 314221 KB)